Core Viewpoint - Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) is facing a class action lawsuit due to allegations of misleading statements regarding its business model and growth prospects during the pandemic [3][5]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from January 14, 2021, to June 5, 2025 [3]. - Allegations include that Petco's pandemic-related growth was unsustainable and that its business model, which focuses on premium pet food, was overstated [3]. - The company is accused of downplaying the severity of issues affecting its business and overstating its ability to achieve sustainable, profitable growth [3]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by August 29, 2025 [4]. - Registration allows shareholders to receive updates on the case and does not incur any costs or obligations [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5]. - The firm aims to hold companies accountable for misleading statements that inflate stock prices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. Allegations Against Sarepta Therapeutics - The complaint alleges that Sarepta Therapeutics made materially false and/or misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [3]. - Specific allegations include: - ELEVIDYS poses significant safety risks to patients [3]. - The trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Next Steps for Shareholders - Shareholders are advised to register for the class action by August 25, 2025, to participate in the case [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Schall Law Firm is investigating Telix Pharmaceuticals Limited for potential violations of securities laws related to misleading statements and undisclosed information regarding its prostate cancer therapeutic candidates [1][2]. Group 1: Investigation Details - The investigation centers on whether Telix issued false or misleading statements and failed to disclose relevant information to investors [2]. - On July 22, 2025, Telix announced it received a subpoena from the SEC concerning its disclosures about the development of its prostate cancer therapeutic candidates [2]. - Following the SEC subpoena announcement, Telix's American Depositary Receipts (ADRs) experienced a decline of over 10.4% the next day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of NorthWestern Energy by Black Hills Corp, which will result in NorthWestern Energy stockholders receiving 0.98 shares of Black Hills common stock for each share they hold [1] Group 1 - The acquisition is expected to close in the latter half of 2026 [1] - NorthWestern Energy stockholders are projected to own approximately 44% of the combined company post-acquisition [1]

Core Viewpoint - The Schall Law Firm is investigating Albany International Corp. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Albany issued false or misleading statements and failed to disclose relevant information to investors [2]. - Albany reported Q2 2025 financial results on July 30, 2025, showing non-GAAP earnings per share that significantly missed consensus estimates [2]. - The President and CEO of Albany acknowledged that earnings "lagged our expectations," attributing this to "certain timing and operational issues" [2]. Group 2: Market Reaction - Following the disappointing earnings report, shares of Albany fell by more than 23.6% the next day [2].

Core Viewpoint - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for alleged violations of securities laws, specifically related to misleading statements about the efficacy of its lung cancer treatment, poziotinib [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 17, 2022, to September 22, 2022, with a deadline for lead plaintiff appointments set for September 24, 2025 [2]. - The complaint alleges that Spectrum made false and misleading statements regarding the results of its Pinnacle Study for poziotinib, which were less favorable than presented to investors [2]. Group 2: Shareholder Participation - Shareholders who purchased SPPI shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint claims that during the class period from March 24, 2023, to May 14, 2025, Biohaven overstated the regulatory prospects of its product candidate, troriluzole, as a treatment for SCA [1]. - It is alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were also overstated [1]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline of September 12, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Schall Law Firm is investigating Fortinet, Inc. for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Fortinet issued false or misleading statements and failed to disclose critical information to investors [2]. - Fortinet's Q2 financial results, reported on August 6, 2025, have raised concerns among investors, particularly regarding the company's statement that 40% to 50% of its accelerated firewall refresh, estimated at $450 million and 650,000 units, was completed [2]. - Following the Q2 results and the confusion surrounding product revenue growth, Fortinet's shares dropped by 25.3% on August 7, 2025 [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed issues affecting the company's performance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from November 7, 2024, to July 8, 2025, RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [1]. - It is claimed that the defendants overstated the demand for RxSight's products [1]. - As a result of these issues, RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [1]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - Shareholders who purchased shares of RXST during the specified class period are encouraged to register for the class action, with a deadline of September 22, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Petco Health and Wellness Company, Inc. regarding a class action lawsuit related to misleading statements made by the company during the class period from January 14, 2021, to June 5, 2025 [3]. Group 1: Allegations Against Petco - Allegations include that Petco's pandemic-related growth was not sustainable and that its business model focused on premium pet food was overstated [3]. - The strength of Petco's differentiated product strategy was claimed to be exaggerated, and the company downplayed the severity of issues affecting its business [3]. - Defendants allegedly overstated Petco's ability to achieve sustainable, profitable growth, leading to materially false and misleading public statements [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is August 29, 2025, and participation does not incur any cost or obligation [4]. - Shareholders who register will receive updates through a portfolio monitoring software regarding the status of the case [4]. - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements by the company [5].